Form D · Biotechnology
Everist Genomics, Inc.
Ann Arbor, MI · CIK 0001542521
Offering snapshot reported Sep 4, 2012 · SEC filing
- Reported sold
- $3.06M Offering amount: $30M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $35K Reported outside-investor minimum
- First sale
- Aug 21, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 4, 2012 | Initial | $3,061,999 | No comparison | 11 | SEC filing |
| Feb 16, 2012 | Initial | $9,479,766 | No comparison | 25 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-183573
Source: Form D, filed Sep 4, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alex Charlton | Director, Executive |
| Randal Charlton | Director |
| Steve Everist | Director |
| Tom Everist | Director, Executive |
| Thomas Stephen Everist | Director |
| Prasad Sunkara | Director, Executive |
| William P Worzel | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
709 West Ellsworth Road 2 Nd Floor
Ann Arbor, MI, 48108
Ann Arbor, MI, 48108